A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

BACKGROUND Fetal-globin (gamma-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the beta-globin chains that are defective or absent in patients with the beta-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in gamma-globin--gene expression in the developing fetus, cultured cells, and animal models. METHODS To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with beta-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of gamma-globin messenger RNA (mRNA) were determined before and during treatment. RESULTS In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P < 0.01). The proportion of F reticulocytes increased about twofold, and the level of gamma-globin mRNA increased twofold to sixfold. The increase in gamma-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. CONCLUSIONS In patients with beta-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate beta-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or beta-thalassemia.

[1]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[2]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[3]  D. Linch,et al.  Determination of the hemoglobin F program in human progenitor-derived erythroid cells. , 1985, The Journal of clinical investigation.

[4]  G. Stamatoyannopoulos,et al.  On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. , 1989 .

[5]  G. Brittenham,et al.  Sickle cell anemia and trait in a population of southern india , 1977, American journal of hematology.

[6]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[7]  S. Karlsson,et al.  Developmental regulation of human globin genes. , 1985, Annual review of biochemistry.

[8]  D. Faller,et al.  Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. , 1989, Blood.

[9]  G. Dover,et al.  Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. , 1987, Blood.

[10]  T. Ley,et al.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.

[11]  J. Little,et al.  5'-flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells , 1991, Molecular and cellular biology.

[12]  J. Clegg,et al.  Abnormal human haemoglobins , 1966 .

[13]  D. Weatherall,et al.  Developmental genetics of the human haemoglobins. , 1983, The Biochemical journal.

[14]  H. Witkowska,et al.  Electrospray mass spectrometry in the clinical diagnosis of variant hemoglobins. , 1991, Journal of chromatography.

[15]  G. Stamatoyannopoulos,et al.  Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. , 1985, The New England journal of medicine.

[16]  A. Sarnaik,et al.  Quantification of short-chain fatty acids in plasma. , 1982, Clinical chemistry.

[17]  R. Miniero,et al.  The Importance of the Genetic Picture and Globin Synthesis in Determining the Clinical and Haematological Features of Thalassaemia Intermedia , 1979, British journal of haematology.

[18]  D. Faller,et al.  Delay in the fetal globin switch in infants of diabetic mothers. , 1985, The New England journal of medicine.

[19]  E. Orringer,et al.  Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. , 1992, The New England journal of medicine.

[20]  L. Pauling,et al.  Sickle cell anemia a molecular disease. , 1949, Science.

[21]  M. Goldberg,et al.  Participation of hemoglobins A and F in polymerization of sickle hemoglobin. , 1977, The Journal of biological chemistry.

[22]  J. Clegg,et al.  Benign sickle-cell anaemia. , 1972, British journal of haematology.

[23]  A. Schechter,et al.  Levels of fetal hemoglobin necessary for treatment of sickle cell disease. , 1988, The New England journal of medicine.

[24]  A. Schechter,et al.  5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia , 1983 .

[25]  S. J. Chen,et al.  Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. McIntyre,et al.  Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. , 1984, The New England journal of medicine.

[27]  E. Kurschel,et al.  Clinical pharmacology of sodium butyrate in patients with acute leukemia. , 1987, European journal of cancer & clinical oncology.

[28]  I. Tardivel,et al.  Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[29]  T. Ley,et al.  Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. , 1986, Blood.

[30]  A. Ravid,et al.  Effect of polar organic compounds on leukemic cells: Butyrate‐induced partial remission of acute myelogenous leukemia in a child , 1983, Cancer.

[31]  D. Weatherall,et al.  Hb F Synthesis in Sickle Cell Anaemia: a Comparison of Saudi Arab Cases with those of African Origin , 1980, British journal of haematology.

[32]  M. Whitters,et al.  Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Stamatoyannopoulos,et al.  Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. , 1987, The New England journal of medicine.

[34]  V. Ingram,et al.  A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin , 1956, Nature.

[35]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[36]  S. Cai,et al.  Identification of the multiple beta-thalassemia mutations by denaturing gradient gel electrophoresis. , 1990, The Journal of clinical investigation.

[37]  D. Zwiers,et al.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Burns,et al.  Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. , 1988, Blood.